NovaBay Pharmaceuticals Files 8-K Report
Ticker: NBY · Form: 8-K · Filed: Jul 11, 2024 · CIK: 1389545
Sentiment: neutral
Topics: 8-K, financial-condition, operations
TL;DR
NovaBay dropped an 8-K on 7/11 covering financials and operations.
AI Summary
On July 11, 2024, NovaBay Pharmaceuticals, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of operations and financial condition, as well as Regulation FD disclosures and financial statements. The report was filed as of July 11, 2024, with the SEC.
Why It Matters
This 8-K filing provides crucial updates on NovaBay Pharmaceuticals' financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for operational and financial updates, not indicating any immediate or specific new risks.
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- July 11, 2024 (date) — Date of earliest event reported
- 2000 Powell Street, Suite 1150, Emeryville, CA 94608 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by NovaBay Pharmaceuticals?
The primary purpose of this 8-K filing is to report on NovaBay Pharmaceuticals' results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 11, 2024.
What is NovaBay Pharmaceuticals' state of incorporation?
NovaBay Pharmaceuticals, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for NovaBay Pharmaceuticals?
The IRS Employer Identification Number for NovaBay Pharmaceuticals is 68-0454536.
Where are NovaBay Pharmaceuticals' principal executive offices located?
NovaBay Pharmaceuticals' principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-07-11 08:45:30
Key Financial Figures
- $0.01 — h Registered Common Stock , par value $0.01 per share NBY NYSE American Indicat
Filing Documents
- nby20240711_8k.htm (8-K) — 29KB
- ex_697249.htm (EX-99.1) — 16KB
- logo.jpg (GRAPHIC) — 4KB
- 0001437749-24-022526.txt ( ) — 189KB
- nby-20240711.xsd (EX-101.SCH) — 3KB
- nby-20240711_def.xml (EX-101.DEF) — 12KB
- nby-20240711_lab.xml (EX-101.LAB) — 15KB
- nby-20240711_pre.xml (EX-101.PRE) — 12KB
- nby20240711_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On July 11, 2024, NovaBay Pharmaceuticals, Inc. (the "Company") issued a press release announcing its preliminary second quarter 2024 net revenue and financial results expectations. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated by reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, are intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Language Concerning Forward-Looking Statements This release contains forward looking statements within the meaning of the " safe harbor " provisions of the Private Securities Litigation Reform Act of 1995. This release contains forward-looking statements that are based upon management ' s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the Company ' s business strategies, current and projected revenue sources, expected future revenue, customer loyalty and satisfaction, as well as generally the Company ' s expected future financial results. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Other risks relating to the Company ' s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company ' s latest Form 10-K, subsequent Forms 10-Q and/or registration statement filings with the Securities and Exchange Commission, especially under the heading " Risk Factors. " The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update public
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated July 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovaBay Pharmaceuticals, Inc. By: /s/ Justin Hall Justin Hall Chief Executive Officer and General Counsel Dated: July 11, 2024